Antibody-Drug Conjugates – Page 3

AstraZeneca Unveils In-House ADCs, Rivaling AbbVie and Pfizer’s Cancer Therapies

7 months ago talkbio0Tagged AbbVie, Antibody-Drug, Antibody-Drug Conjugates, AstraZeneca, Biotechnology, Daiichi, Immunostimulating conjugate (antigen), Neoplasms, Pfizer, Sankyo

AstraZeneca, Daiichi Sankyo, Antibody-Drug Conjugates (ADCs), Cancer Therapies, AbbVie, Pfizer, Oncology, Biotechnology

WCLC24: Merck & Daiichi Sankyo’s ADC Shows Promising Results in Small Cell Lung Cancer

8 months ago talkbio0Tagged Antibody-Drug Conjugates, Co., Daiichi, Deruxtecan, DXd, ifinatamab, Sankyo, Small cell carcinoma of lung, Technology, therapeutic autologous dendritic cells, WCLC24

WCLC24, Merck & Co., Daiichi Sankyo, ADC (Antibody Drug Conjugate), SCLC (Small Cell Lung Cancer), Ifinatamab Deruxtecan, DXd ADC Technology

Merck & Co. Expands Oncology Pipeline with Kelun-Biotech ADCs

8 months ago talkbio0Tagged Antibody-Drug, Antibody-Drug Conjugates, Immunostimulating conjugate (antigen), Kelun-Biotech, Malignant Neoplasms, Merck & Co., Oncology Pipeline

Merck & Co., Kelun-Biotech, Antibody-Drug Conjugates (ADCs), Cancer Treatment, Oncology Pipeline

Adcendo Secures $1 Billion Deal for Multitude’s Anti-TF ADC

8 months ago talkbio0Tagged Adcendo, anti-TF ADC, Antibody-Drug Conjugates, biobucks, Cancer Therapeutic Procedure, therapeutic autologous dendritic cells

Adcendo, Multitude Therapeutics, anti-TF ADC, $1 billion deal, biobucks, antibody-drug conjugate, cancer treatment

Ipsen Licenses Second ADC via $1B Bet on Foreseen Bio Asset

10 months ago talkbio0Tagged Antibody-Drug Conjugates, Billion, Ipsen

Ipsen, Foreseen Biotechnology, Antibody-Drug Conjugate (ADC), Licensing Agreement, $1 Billion Deal

Ipsen Licenses Novel Antibody-Drug Conjugate from Foreseen Biotechnology for Cancer Treatment

10 months ago talkbio0Tagged Antibody-Drug Conjugates, FS001, Global Licensing Agreement, Ipsen, Malignant Neoplasms

Ipsen, Foreseen Biotechnology, Antibody-Drug Conjugate (ADC), Cancer Treatment, Global Licensing Agreement, FS001

Bristol Myers Squibb Ends Collaboration with Eisai on Antibody-Drug Conjugate Due to Portfolio Prioritization

10 months ago talkbio0Tagged Antibody-Drug Conjugates, Collaboration, ecteribulin, Eisai, farletuzumab, Myers, portfolio, Prioritization, squibb

Bristol Myers Squibb, Eisai, Antibody-Drug Conjugate, Portfolio Prioritization, Collaboration, Farletuzumab Ecteribulin

Merck and Daiichi Sankyo’s ADC Pact Hits Regulatory Setback in FDA Rejection

10 months ago talkbio0Tagged Antibody-Drug Conjugates, Daiichi, Deruxtecan, HER3 protein, Merck, Non-Small Cell Lung Carcinoma, patritumab, Regulatory Setback, Rejection (Psychology), Sankyo, United States Food and Drug Administration

Merck, Daiichi Sankyo, Antibody-Drug Conjugate (ADC), Patritumab Deruxtecan, FDA Rejection, Regulatory Setback, HER3 Protein, Non-Small Cell Lung Cancer (NSCLC)

Day One Biopharma Expands Pipeline with $55 Million Acquisition of MabCare’s Phase 1-Ready ADC

10 months ago talkbio0Tagged Acquisition (action), Antibody-Drug Conjugates, Biopharma, biotech, Daily, expansion, MabCare, Malignant Neoplasms, pipeline, PTK7 protein, human

Day One Biopharma, MabCare, Antibody Drug Conjugate (ADC), PTK7, Cancer Treatment, Biotech Acquisition, Pipeline Expansion

AbbVie Achieves Early Return on Investment with $10 Billion Immunogen Acquisition Following Phase II Ovarian Cancer Success

11 months ago talkbio0Tagged AbbVie, Antibody-Drug Conjugates, Antigens, Elahere, ovarian neoplasm, Phase 2 Clinical Trials, Return on Investment, ROI

AbbVie, Immunogen, Ovarian Cancer, Phase II Trial, Return on Investment (ROI), Antibody-Drug Conjugate (ADC), Elahere